Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))

Phase I Clinical Trial of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Advanced Multiple Myeloma

The purposes of this study are:

• To determine the maximum tolerated dose (MTD) for the combination of oral vorinostat and bortezomib in participants with advanced multiple myeloma
• To assess the safety and tolerability of this regimen and to document the participant's clinical status (by anti-tumor activity) for this combination, as determined per standard of care.

Inclusion Criteria:

• Adults with refractory or relapsed multiple myeloma
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (a measurement to determine participant's ability to perform daily activities)
• Adequate bone marrow reserve
• Adequate hepatic and renal function
• Ability to swallow capsules
• 3 weeks or more since prior chemotherapy and have recovered from prior toxicities

Exclusion Criteria:

• Participants who plan to have a bone marrow transplant within 4 weeks of start of treatment
• Participants with prior treatment with other investigational agents with a similar anti-tumor mechanism
• Participants with other active/uncontrolled clinically significant illness
• Pregnant or nursing female participants
• Participants who received bortezomib within 3 months of start of this trial